Nirmatrelvir and Ritonavir Combination in COVID-19 Patients With Advanced Chronic Kidney Disease

Authors:

Abstract
To the Editor—We read with great interest the work by Chan and colleagues evaluating nirmatrelvir-ritonavir (NMV/r) treatment among 59 patients with mild coronavirus disease 2019 (COVID-19) and advanced chronic kidney disease (CKD) [ 1]. They showed that a modified dose of NMV/r effectively suppressed the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load with a favorable safety profile. Unfortunately, they did not provide pharmacokinetics of NMV/r. We report the experience of NMV/v use in patients with advanced CKD, and we provide pharmacokinetics of NMV/r among those patients. Thirteen patients with glomerular filtration rate (GFR) <30 mL/minute (including 2 patients on dialysis) presenting with mild COVID-19 were treated from December 2022 to April 2023 with a modified dose of NMV/r (NMV/r 300/100 mg on day 1, NMV/r 150/100 mg on days 2–5), after a median time of 2 days following onset of symptoms. Median age was 70 years, and 54% of patients were immunocompromised. At diagnosis, 70% of patients were hospitalized; none received oxygen therapy. Diagnosis was made on polymerase chain reaction (PCR), and 75% were infected with Omicron BQ1.1. NMV/r plasma concentration was assessed for 10 patients, including 17 samples, after a median of 3.5 days from onset of NMV/r therapy ( Figure 1). Only 1 patient had NMV/r plasma concentration measured before and after a 4-hour hemodialysis. Nirmatrelvir (NMV) and ritonavir (RTV) plasma concentrations fell respectively by 29.6% (from 6987 to 4919 ng/mL) and 41.2% (from 743 to 444 ng/mL). At day 28, all patients were alive and asymptomatic. No major adverse event leading to NMV/r discontinuation was observed.

This publication has 7 references indexed in Scilit: